Background: Cilostazol is frequently used to treat and prevent thrombosis in Korean patients.
Patients and methods: We performed the pharmacokinetic and correlation analysis of cilostazol in Korean healthy subjects. A total of male 78 volunteers was subjected to three separate bioequivalence studies in which 100 mg of cilostazol was administered. AUC, t(1/2), and C(max) were 12,100 ± 4,880 ng×h/ ml, 11.1 ± 4.4 hours, and 827 ± 361 ng/ml, respectively.
Results: ALT was positively correlated with age and C(max) was positively correlated with AUC, but negatively correlated with body weight.
Conclusion: We suggest that the unique pharmacokinetic parameters and interrelationship can help to understand the pharmacokinetics of cilostazol in Korean subjects.